Objective: To determine the incidence of and risk factors for dose-limiting chemotherapy induced peripheral neuropathy (CIPN) in non-metastatic breast cancer. Methods: This retrospective cohort study included 488 women with an adjuvant or neoadjuvant treatment plan with docetaxel or paclitaxel from June 1, 2009 to December 31, 2011. Exclusion criteria were: metastatic disease, previous neurotoxic chemotherapy, pre-existing neuropathy, pregnant or within 3 months post-partum, and prosthetic limb. The primary outcome was dose-limiting CIPN, defined as a treatment modification event (dose delay, dose reduction, or treatment discontinuation) attributed to CIPN. The primary risk factor of interest was obesity (BMI≥30). Covariates included race, age, menopausal status, diabetes, and other comorbidities, node status, tumor size, regimen, and oncologist. With 80% power and 0.05 type I error rate, the study could detect a risk ratio of 1.8 in the obese versus non-obese. Results: Fifty (10.2%) women had a treatment modification event attributed to CIPN (TM-CIPN). TM-CIPN incidence differed significantly by agent (docetaxel = 2.4% (N = 5/209), paclitaxel=16.1% (N = 45/279); p < 0.001). In analyses restricted to patients treated with paclitaxel with complete covariate data (N = 273), the odds of TM-CIPN did not differ by obesity, OR = 1.17 (95% CI 0.59–2.35). After adjusting for black race, menopausal status, disease severity, and type II diabetes the TM-CIPN and obesity association was attenuated. The attenuation occurred after adjustment for black race, which was a confounder of the obesity and TM-CIPN relationship, and associated with obesity (OR = 3.78, p = <0.001). Post-menopausal status, disease severity, and type II diabetes were associated with obesity, but were not confounders. Compared to whites, and after controlling for disease severity, menopausal status, and oncologist, blacks and other non-whites had significantly increased odds of CIPN-TM (OR = 2.5, p < 0.02; OR = 4.8, p < 0.01; respectively). Tests of homogeneity indicated the race and TM-CIPN association was not modified by oncologist or disease severity. Conclusion: Obese and non-obese women have a comparable likelihood of having their treatment modified due to CIPN. Women of racial minorities had over 2-to 4-fold increased odds of TM-CIPN compared to white women. Investigations addressing the mechanistic explanations for this association are warranted. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-13-01.

Patients with COPD are required to take long-term treatments to treat their chronic disease and avoid further complications. However, lack of adherence is very common and represents major barriers to treatment efficiency. Measuring patient acceptance of their medication should help to better understand and predict patients' medication-taking behavior. Objectives: The objectives of this study are to evaluate the level of acceptance to medication in patients with COPD in real life; to identify issues and to define priorities for action. MethOds: This is an observational, crosssectional study conducted in Europe using Carenity Online Community. Adult COPD patients were invited to complete an online questionnaire including a validated patient reported outcome measure: the 25-item ACCEptance by the Patients of their Treatment (ACCEPT©). It includes one general acceptance dimension (Acceptance/ General) and five multi-item treatment-attribute specific dimensions: Acceptance/ Medication Inconvenience, Acceptance/Long-term Treatment, Acceptance/Regimen Constraints, Acceptance/Side Effects, Acceptance/Effectiveness, scored from 0-100 (lowest to highest acceptance). Patients were categorized according to their main treatment class: adrenergics, inhalants; other drugs for obstructive airway diseases, inhalants; other COPD treatment. Results: 117 patients with COPD were included. Mean Acceptance/General score was of 56.27 ± 33.95. Significant differences (p < 0.05) were found between groups defined by treatment class on Acceptance/ General and Acceptance/Effectiveness. Pearson correlations showed Acceptance/ General to be highly correlated with Acceptance/ Effectiveness (R = 0.64). Having side effects and their unpleasantness were the main reported issues. cOnclusiOns: Treatment acceptance is not satisfactory in COPD. Patients' treatment acceptance is primarily driven by its effectiveness and limitations for COPD. These findings give indications about patients' priorities and unmet needs for COPD.